<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">microcirculation</journal-id><journal-title-group><journal-title xml:lang="ru">Регионарное кровообращение и микроциркуляция</journal-title><trans-title-group xml:lang="en"><trans-title>Regional blood circulation and microcirculation</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-6655</issn><issn pub-type="epub">2712-9756</issn><publisher><publisher-name>Academician I.P. Pavlov First St. Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24884/1682-6655-2019-18-3-5-8</article-id><article-id custom-type="elpub" pub-id-type="custom">microcirculation-435</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Микроваскулярная дисфункция миокарда у больных с ишемической болезнью сердца и способы ее коррекции</article-title><trans-title-group xml:lang="en"><trans-title>Microvascular dysfunction of myocardium in patients with ischemic heart desease and ways of its correction</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андриевских</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Andrievskikh</surname><given-names>S. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>анд. мед. наук, зав. кардиохирургическим отделением</p></bio><bio xml:lang="en"><p>Candidate of Medical Sciences, Head of the Cardiac Surgery Department № 1</p></bio><email xlink:type="simple">astas76@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хубулава</surname><given-names>Г. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Khubulava</surname><given-names>G. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>академик РАН, д-р мед. наук, профессор, полковник медицинской службы, начальник 1-й кафедры хирургии усовершенствования врачей имени академика П. А. Куприянова</p></bio><bio xml:lang="en"><p>Academician of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, Colonel of the Medical Service, Head of the 1st Department of Surgery of the Advanced Medical School named after Academician P. A. Kupriyanov</p></bio><email xlink:type="simple">ggkh07@rambler.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетной учреждение «Федеральный центр сердечно-сосудистой хирургии» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal center for cardiovascular surgery</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное военное образовательное учреждение высшего образования «Военномедицинская академия имени С. М. Кирова» Министерства обороны Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Military Medical Academy named after S. M. Kirov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>06</day><month>10</month><year>2019</year></pub-date><volume>18</volume><issue>3</issue><fpage>5</fpage><lpage>8</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Андриевских С.И., Хубулава Г.Г., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Андриевских С.И., Хубулава Г.Г.</copyright-holder><copyright-holder xml:lang="en">Andrievskikh S.I., Khubulava G.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.microcirc.ru/jour/article/view/435">https://www.microcirc.ru/jour/article/view/435</self-uri><abstract><p>Современные успехи медикаментозного и хирургического лечения ишемической болезни сердца, к сожалению, не решат всего арсенала проблем, связанных с нарушением микроциркуляторной перфузии миокарда. Предложенные методы воздействия на микроваскулярную дисфункцию ишемизированного миокарда, к которым, в том числе, относятся клеточная кардиомиопластика и лазерная тунелизация миокарда, оказывают относительно непродолжительный позитивный эффект. Для более успешного применения этих современных подходов существенную роль играет повышение компенсаторно-репаративных возможностей у этих больных. Положительный результат лечения в таком случае может быть достигнут применением пред- и послеоперационной иммунокоррекции, поскольку все эти процессы носят иммунообусловленный характер.</p></abstract><trans-abstract xml:lang="en"><p>Modern advances in the medical and surgical treatment of coronary heart disease (CHD), unfortunately, will not solve the entire arsenal of problems, associated with impaired microcirculatory myocardial perfusion. The proposed methods of influence on microvascular dysfunction of the ischemic myocardium, including cell cardiomyoplasty and laser myocardial tunneling, include a relatively short-lasting positive effect. For a more successful application of these modern approaches, an increase in the compensatory-reparative capabilities in these patients plays a significant role. A positive result of treatment, in this case, can be achieved by applying pre- and postoperative immunocorrection, since all these processes are immuno-conditioned.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>микроваскулярная дисфункция</kwd><kwd>трансмиокардиальная лазерная тунелизация</kwd><kwd>иммунокоррекция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>micro vascular dysfunction</kwd><kwd>transmyocardial laser revascularization</kwd><kwd>immune correction</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Вишневский А. Г., Андреев Е. М., Тимонин С. А. Смертность от болезней системы кровообращения и продолжительность жизни в России // Демограф. обозрение. – 2016. – Т. 3, № 1. – С. 6–34.</mixed-citation><mixed-citation xml:lang="en">[Vishnevsky AG, Andreev EM, Timonin SA. Mortality from cardiovascular diseases and life expectancy in Russia. Demograﬁc review. 2016;3(1):6–34. (In. Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И. Е., Мычка В. Б. Метаболический синдром. – М.: Медиа Медика, 2008. – 324 с.</mixed-citation><mixed-citation xml:lang="en">Chazova IE, Mychka VB. Metabolic syndrome. Moscow, Media Medica, 2008:324. (In. Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Murthy V, Naya M, Taqueti V et al. Effects of gender on coronary microvascular dysfunction and cardiac outcomes. Circulation. 2014;129:2518–2527. Doi: 10.1161/ CIRCULATIONAHA.113.008507.</mixed-citation><mixed-citation xml:lang="en">Murthy V, Naya M, Taqueti V et al. Effects of gender on coronary microvascular dysfunction and cardiac outcomes. Circulation. 2014;129:2518–2527. Doi: 10.1161/ CIRCULATIONAHA.113.008507.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Беришвили И. И. Трансмиокардиальная лазерная реваскуляризация. Вторая жизнь: в 2 т. – М.: ГЕОС, 2016.</mixed-citation><mixed-citation xml:lang="en">[Berishvili II. Tranmyocardial laser revascularisation. Second life. In 2 volumes. Moscow, GEOS, 2016. (In. Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kern MJ, Lerman A, Bech J-W et al. Physiological assessment of coronary artery disease in the cardiac catheterization laboratory: a scientiﬁc statement from the American Heart Association Committee on diagnostic and interventional cardiac catheterization, council on clinical cardiology. Circulation. 2006;114:1321¬– 1341. Doi: 10.1161/ CIRCULATIONAHA. 106.177276.</mixed-citation><mixed-citation xml:lang="en">Kern MJ, Lerman A, Bech J-W et al. Physiological assessment of coronary artery disease in the cardiac catheterization laboratory: a scientiﬁc statement from the American Heart Association Committee on diagnostic and interventional cardiac catheterization, council on clinical cardiology. Circulation. 2006;114:1321¬– 1341. Doi: 10.1161/ CIRCULATIONAHA. 106.177276.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Е. Эндотелиальная дисфункция при сердечной недостаточности: возможности терапии ингибиторами ангиотензинпревращающего фермента // Кардиология. – 2001. – № 5. – C. 100–104.</mixed-citation><mixed-citation xml:lang="en">Belenkov YuN, Mareev VYu, Ageev FE. Endothelial dysfunction in heart failure: possibilities of therapy with angiotensin-converting enzyme inhibitors. Cardiology. 2011;(5):100–104. (In. Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Бокерия Л. А, Бокерия О. Л, Донаканян С. А. и др. Состояние NO-зависимой аутоарегуляции тканевого кровотока после интервенционного и хирургического лечения идиопатической формы фибрилляции предсердий // Анналы аритмологии. – 2013. – № 3. – С. 136–143.</mixed-citation><mixed-citation xml:lang="en">Bokeria LA, Bokeria OL, Donakyan SA et al. State of no-dependent autoregulation of tissular blood ﬂow after interventional and surgical treatment of idiopathic atrial ﬁbrillation. Annals of arrhythmology. 2013;(3):136–143. (In. Russ.). Doi: 10.15275/ annaritmol.2013.3.3.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Marzilli M. Coronary microcirculation: the new frontier in coronary artery disease. Heart Metab. 2008;38:23–25.</mixed-citation><mixed-citation xml:lang="en">Marzilli M. Coronary microcirculation: the new frontier in coronary artery disease. Heart Metab. 2008;38:23–25.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Muller-Delp JM. The coronary microcirculation in health and disease. ISRN Physiol. 2013; Article ID: 238979:24. Doi: 10.1155/2013/238979.</mixed-citation><mixed-citation xml:lang="en">Muller-Delp JM. The coronary microcirculation in health and disease. ISRN Physiol. 2013; Article ID: 238979:24. Doi: 10.1155/2013/238979.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Li T, Vabadarajan P, Rechenmacher S et al. Abstract 1206: Survival patterns in patients with coronary microvascular dysfunction. Circulation. 2008;118:10085–1086.</mixed-citation><mixed-citation xml:lang="en">Li T, Vabadarajan P, Rechenmacher S et al. Abstract 1206: Survival patterns in patients with coronary microvascular dysfunction. Circulation. 2008;118:10085–1086.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kranenburg van M, Margo M, Thiele H et al. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. JACC Cardiovasc. Imaging. 2014 Sep;7(9):930–939. Doi: 10.1016/j.jcmg.2014.05.010.</mixed-citation><mixed-citation xml:lang="en">Kranenburg van M, Margo M, Thiele H et al. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. JACC Cardiovasc. Imaging. 2014 Sep;7(9):930–939. Doi: 10.1016/j.jcmg.2014.05.010.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Pepine CJ, Anderson RD, Sharaf BL et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Herat, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) study. J. Am. Coll. Cardiol. 2010;55:2825–2832. Doi: 10.1016/j.jacc.2010.01.054.</mixed-citation><mixed-citation xml:lang="en">Pepine CJ, Anderson RD, Sharaf BL et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Herat, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) study. J. Am. Coll. Cardiol. 2010;55:2825–2832. Doi: 10.1016/j.jacc.2010.01.054.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Беришвили И. И., Игнатьева Ю. В., Семенов М. Х. и др. Влияет ли трансмиокардиальная лазерная реваскуляризация на результаты операций у больных ишемической болезнью сердца с диффузным атеросклеротическим поражением коронарных артерий? // Бюл. НЦССХ им. А. Н. Бакулева РАМН. – 2013. – Т. 14, № 6. – С. 52–61.</mixed-citation><mixed-citation xml:lang="en">Berishvili II, Ignat’eva YuV, Semenov MKh, Khvichiya LE, Gusev PV, Vakhromeeva MN. Does transmyocardial laser revascularization inﬂuence the outcomes of surgery in patients with ischemic heart disease with diffuse coronary atherosclerosis? The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2013;14(6):52–61. (In. Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Briones E, Lacalle JR, Marin-Leon I, Rueda JR. Transmyocardial laser revascularization versus medical therapy for refractory angina. Cochrane Database Syst. Rev. 2015;2:CD003712. Doi: 10.1002/14651858.cd003712.pub3.</mixed-citation><mixed-citation xml:lang="en">Briones E, Lacalle JR, Marin-Leon I, Rueda JR. Transmyocardial laser revascularization versus medical therapy for refractory angina. Cochrane Database Syst. Rev. 2015;2:CD003712. Doi: 10.1002/14651858.cd003712.pub3.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Чернявский А. М., Фомичев А. В., Чернявскии М. A. и др. Сравнительная характеристика эффективности методов непрямой реваскуляризации миокарда в хирургии ишемической болезни сердца // Патология кровообращения и кардиохир. – 2013. – Т. 17, № 1. – С. 15–20. Doi: 1681-3472-2013-1-15-20.</mixed-citation><mixed-citation xml:lang="en">Chernyavsky AM, Fomichev AV, Chernyavsky MA, Bondar VYu, Sergeevichev DS. Comparative characteristics of the effectiveness of the methods of indirect myocardial revascularization in surgery of coronary heart disease. Circulation Pathology and Cardiac Surgery. 2013;17(1):15–20. (In. Russ.). Doi: 1681-3472-2013-1-15-20.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Хубулава Г. Г., Козлов К. Л., Кравчук В. Н. и др. Направления клеточной терапии в лечении сердечной недостаточности // Вестн. Рос. военно-мед. акад. – 2016. – № 2 (54). – С. 223–229.</mixed-citation><mixed-citation xml:lang="en">Khubulava GG, Kozlov KL, Kravchuk VN, Shishkevich AN, Mikhailov SS, Lukjanov NG. Directions of cell therapy in the treatment of heart failure. Messenger of Russian military medical academy. 2016;2(54):223–229. (In. Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Андриевских И. А., Лукин О. П., Погорелов Д. Е. Нестабильный патоморфоз, иммунокоррекция и профилактика осложнений в сердечно-сосудистой хирургии // Клин. физиология кровообращения. – 2012. – № 4. – С. 19–24.</mixed-citation><mixed-citation xml:lang="en">Andrievskikh IA, Lukin OP, Pogorelov DE. Unstable patomorfosis, immune correction and complication prophylactic in cardio-vascular surgery. Clinical Physiology of Circulation. 2012;(4):19–24. (In. Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Horvath КA, Greene R, Belkind N et al. Left ventricular functional improvement after transmyocardial laser revascularization. Ann. Thorac. Surg. 1998;66:721-725. Doi: 10.1016/ s0003-4975(98)00735-8.</mixed-citation><mixed-citation xml:lang="en">Horvath КA, Greene R, Belkind N et al. Left ventricular functional improvement after transmyocardial laser revascularization. Ann. Thorac. Surg. 1998;66:721-725. Doi: 10.1016/ s0003-4975(98)00735-8.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Вторушина В. В., Сотникова Н. Ю., Горожанина Т. З. Состояние иммунной системы новорожденных детей с дисплазией соединительной ткани сердца // Мед. иммунология. – 2004. – Т. 6, № 3–5. – С. 377–378.</mixed-citation><mixed-citation xml:lang="en">Vtorushina VV, Sotnicova NYu, Goroganina TZ. The state of the immune system of newborns with connective tissue dysplasia of the heart. Medical immunology. 2004;6(3–5):377–378. (In. Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов Е. Л., Бектова Т. В. Рекомендации по лечению системных васкулитов. URL: http://rheumatolog. ru/system/ﬁles/pdf/nacrec/natrec24.pdf (дата обращения 04.08.2016).</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Bektova TV. Recommendations for the treatment of systemic vasculitis. (In. Russ.). Available at: http://rheumatolog.ru/system/ﬁles/pdf/nacrec/natrec24.pdf (accessed 04.08.2016).</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Баранов А. А. Рекомендации по ведению больных васкулитами (по материалам рекомендаций Европейской антиревматической лиги) // Соврем. ревматология. – 2009. – Т. 3, № 2. – С. 5–9. Doi: 10.14412/1996-7012-2009-531.</mixed-citation><mixed-citation xml:lang="en">Baranov AA. Management recommendations for patients with vacuities (Based on recommendations of European anti reumatological League). Modern Rheumatology J. 2009;3(2):5–9. (In Russ.). Doi: 10.14412/1996-7012-2009-531.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Цинкернагель Р. Основы иммунологии. – М.: Мир, 2008. – 135 с.</mixed-citation><mixed-citation xml:lang="en">Tsinkernagel R. Fundamentals of immunology. Moscow, Mir, 2008:135. (In. Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Наследственные нарушения соединительной ткани. Российские рекомендации ВНОК. – М., 2012. – 78 с.</mixed-citation><mixed-citation xml:lang="en">Inherited connective tissue disorders. Russian recommendations RSCO. Moscow, 2012:78. (In. Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Серов В. В., Шехтер А. Б. Соединительная ткань (функциональная морфология и общая патология). – М.: Медицина, 1981. – 312 с.</mixed-citation><mixed-citation xml:lang="en">Serov VV, Shekhter AB. Connective tissue (functional morphology and general pathology). Moscow, Medicine, 1981:312. (In. Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Стрижаков Л. А., Моисеев С. В., Коган Е. А. и др. Факторы риска атеросклероза и клинико-морфологические сопоставления при системных васкулитах // Научно-практ. ревматология. – 2012. – № 4. – С. 18–23. Doi: 10.14412/1995-4484-2012-1106.</mixed-citation><mixed-citation xml:lang="en">Strizhakov LA, Moiseyev SV, Kogan EA et al. Risk factors for atherosclerosis and clinical and morphological comparisons with systemic vasculitis. Rheumatology Science &amp; Practice. 2012;(4):18–23. (In. Russ.). Doi: 10.14412/1995-4484-2012-1106.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов Е. Л. Антифосфолипидный синдром. – М.: Литтера, 2004. – 440 с.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL. Antiphospholipid syndrome. Moscow, Littera, 2004:440. (In. Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Байракова Ю. В., Григорьев А. М., Баздырев Е. Д. и др. Роль субклинического воспаления в развитии сердечнососудистых осложнений у пациентов после коронарного шунтирования // Ишем. болезнь сердца. – 2013. – № 3. – С. 18–22.</mixed-citation><mixed-citation xml:lang="en">Bairakova AM, Grigoriev AM, Bazdyrev ED et al. The role of subclinic inﬂamation in development of cardiovascular complications in CABG patients. Ischemic heart desease. 2013;(3):18–22. (In. Russ.).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
